Shree Ganesh Remedies Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chandulal Kothia

Chief Executive Officer (CEO)

₹10.2m

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	29.1yrs
Participación del CEO	64.7%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	3.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chandulal Kothia en comparación con los beneficios de Shree Ganesh Remedies?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	₹220m
Sep 30 2023	n/a	n/a	₹215m
Jun 30 2023	n/a	n/a	₹189m
Mar 31 2023	₹10m	₹10m	₹170m
Dec 31 2022	n/a	n/a	₹150m
Sep 30 2022	n/a	n/a	₹148m
Jun 30 2022	n/a	n/a	₹139m
Mar 31 2022	₹10m	₹10m	₹134m
Dec 31 2021	n/a	n/a	₹126m
Sep 30 2021	n/a	n/a	₹112m
Jun 30 2021	n/a	n/a	₹101m
Mar 31 2021	₹6m	₹6m	₹98m
Dec 31 2020	n/a	n/a	₹94m
Sep 30 2020	n/a	n/a	₹92m
Jun 30 2020	n/a	n/a	₹99m
Mar 31 2020	₹5m	₹5m	₹105m
Dec 31 2019	n/a	n/a	₹95m
Sep 30 2019	n/a	n/a	₹86m
Jun 30 2019	n/a	n/a	₹74m
Mar 31 2019	₹3m	₹3m	₹62m
Dec 31 2018	n/a	n/a	₹56m
Sep 30 2018	n/a	n/a	₹49m
Jun 30 2018	n/a	n/a	₹48m
Mar 31 2018	₹5m	₹5m	₹47m

Compensación vs. Mercado: La compensación total de Chandulal($USD122.43K) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD39.36K).

Compensación vs. Ingresos: La compensación de Chandulal ha sido consistente con los resultados de la empresa en el último año.

CEO

Chandulal Kothia (60 yo)

29.1yrs

Permanencia

₹10,200,000

Compensación

Mr. Chandulal Manubhai Kothia is Promoter, Chairman and Managing Director of Shree Ganesh Remedies Limited. Mr. Kothia has experience of more than two decades in the field of Manufacturing of pharmaceutica...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Chandulal Kothia	Chairman & MD	29.1yrs	₹10.20m	64.66% ₹ 5.2b
Parth Kothia	Whole Time Director & CFO	3.8yrs	₹4.20m	0.070% ₹ 5.6m
Gunjan Kothia	Whole Time Director	4.1yrs	₹5.10m	0.93% ₹ 75.1m
Priyam Shah	Independent Director	6.6yrs	₹30.00k	sin datos
Maulikkumar Sudani	Independent Director	less than a year	sin datos	sin datos
Parulben Sahani	Independent Director	less than a year	sin datos	sin datos

3.9yrs

Permanencia media

32yo

Promedio de edad

Junta con experiencia: La junta directiva de 540737 se considera experimentada (3.8 años de antigüedad promedio).

Shree Ganesh Remedies Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Shree Ganesh Remedies Limited Announces Company Secretary and Compliance Officer Changes

Shree Ganesh Remedies Limited Announces Director Appointments

Shree Ganesh Remedies Limited, Annual General Meeting, Sep 18, 2023

Whole Time Director & CFO recently bought ₹1.5m worth of stock

Shree Ganesh Remedies Limited Announces Appointment of Parth Kothia as Chief Financial Officer

Shree Ganesh Remedies Limited Announces Resignation of Suresh Panchal as Chief Financial Officer

Recent updates

New minor risk - Market cap size

Shree Ganesh Remedies Limited Announces Company Secretary and Compliance Officer Changes

Third quarter 2024 earnings released: EPS: ₹3.84 (vs ₹3.62 in 3Q 2023)

Shree Ganesh Remedies Limited to Report Q3, 2024 Results on Feb 12, 2024

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Investor sentiment improves as stock rises 22%

Shree Ganesh Remedies Limited to Report Q2, 2024 Results on Nov 10, 2023

Shree Ganesh Remedies Limited Announces Director Appointments

Investor sentiment improves as stock rises 16%

Upcoming dividend of ₹0.50 per share at 0.1% yield

Shree Ganesh Remedies Limited Proposes Final Dividend for Financial Year 2022-23, Payable on 25 September, 2023

Shree Ganesh Remedies Limited, Annual General Meeting, Sep 18, 2023

First quarter 2024 earnings released: EPS: ₹3.86 (vs ₹2.39 in 1Q 2023)

New major risk - Share price stability

Investor sentiment improves as stock rises 16%

Full year 2023 earnings released: EPS: ₹13.86 (vs ₹11.16 in FY 2022)

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 16%

Whole Time Director & CFO recently bought ₹1.5m worth of stock

Shree Ganesh Remedies Limited Announces Appointment of Parth Kothia as Chief Financial Officer

Third quarter 2023 earnings released: EPS: ₹3.62 (vs ₹3.50 in 3Q 2022)

Shree Ganesh Remedies Limited Announces Resignation of Suresh Panchal as Chief Financial Officer

Investor sentiment improved over the past week

Second quarter 2023 earnings released: EPS: ₹3.28 (vs ₹2.52 in 2Q 2022)

Shree Ganesh Remedies Limited to Report Q3, 2022 Results on Oct 23, 2022

Upcoming dividend of ₹0.50 per share

Shree Ganesh Remedies Limited, Annual General Meeting, Sep 28, 2022

First quarter 2023 earnings released: EPS: ₹2.39 (vs ₹2.23 in 1Q 2022)

Shree Ganesh Remedies Limited to Report Q1, 2023 Results on Jul 12, 2022

Full year 2022 earnings released: EPS: ₹11.16 (vs ₹8.12 in FY 2021)

Shree Ganesh Remedies Limited Recommends Final Dividend for the Year Ended March 31, 2022

Prakash Zaverbhai Boghra and Kevin Divyesh Thakor agreed to acquire Akshar Jyot Private Limited from Shree Ganesh Remedies Limited (BSE:540737) for INR 1,00,000.

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS ₹2.52 (vs ₹2.58 in 2Q 2021)

Investor sentiment improved over the past week

Shree Ganesh Remedies Limited (BSE:540737) acquired Akshar Jyot Private Limited from its shareholders for INR 0.1 million.

Shree Ganesh Remedies Limited (BSE:540737) entered into an agreement to acquire a 74% stake in Dhari Chemicals Limited for INR 0.07 million.

Upcoming dividend of ₹1.75 per share

Compliance Officer & Company Secretary Aditya Patel has left the company

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Shree Ganesh Remedies Limited Announces Development of New Product

Shree Ganesh Remedies Limited Recommends Final Dividend for the Financial Year Ended March 31, 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: ₹183

Shree Ganesh Remedies Limited Announces Board Changes

Shree Ganesh Remedies Limited to Report Q3, 2021 Results on Jan 18, 2021

Investor sentiment improved over the past week

New 90-day high: ₹165

Market bids up stock over the past week

New 90-day high: ₹135

Shree Ganesh Remedies Limited Announces Board Changes

Shree Ganesh Remedies Limited to Report First Half, 2021 Results on Oct 08, 2020

New 90-day high: ₹150

New 90-day high - ₹117

Full year earnings released - EPS ₹11.67

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad